Related Experiment Video
Updated: May 1, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin
Xuejiao Liu1, Mingshan Niu, Xiaoyu Xu
1Laboratory of Neurosurgery, Xuzhou Medical College, China.
Abstract:
Plumbagin, a naphthoquinone derived from the medicinal plant Plumbago zeylanica, has been shown to exert anti-cancer and anti-proliferative activities in vitro as well as in animal tumor models. However, the mechanism underlying its anti-tumor action still remains unclear. CRM1 is a nuclear export receptor involved in the active transport of tumor suppressors whose function is altered in cancer due to increased expression and overactive transport. We showed that CRM1 is a direct cellular target of plumbagin. The nuclei of cells incubated with plumbagin accumulated tumor-suppressor proteins and inhibited the interactions between CRM1 and these proteins. Particularly, we demonstrated that plumbagin could specifically react with the conserved Cys(528) of CRM1 but not with a Cys(528) mutant peptide through Mass spectrometric analysis. More importantly, cancer cells that are transfected with mutant CRM1 (C528S) are resistant to the inhibitory effects of plumbagin, demonstrating that the inhibition is through direct interaction with Cys(528) of CRM1. The inhibition of nuclear traffic by plumbagin may account for its therapeutic properties in cancer and inflammatory diseases. Our findings could contribute to the development of a new class of CRM1 inhibitors.
Insights
Plumbagin, a compound from Plumbago zeylanica, inhibits cancer growth by targeting CRM1 (chromosome region maintenance 1). This interaction prevents tumor suppressor proteins from being exported from the nucleus, revealing a new therapeutic mechanism.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Plumbagin from Plumbago zeylanica exhibits anti-cancer properties, but its mechanism is unclear.
- CRM1 (chromosome region maintenance 1) is a nuclear export receptor implicated in cancer progression.
- CRM1's altered function in cancer involves increased expression and overactive transport of tumor suppressors.
Purpose of the Study:
- To elucidate the molecular mechanism of plumbagin's anti-tumor activity.
- To identify CRM1 as a direct cellular target of plumbagin.
- To explore the therapeutic potential of targeting CRM1 with plumbagin.
Main Methods:
- Cellular assays to observe protein localization and interactions.
- Mass spectrometric analysis to identify specific binding sites.
- Transfection of cancer cells with mutant CRM1 (C528S) to assess plumbagin resistance.
Main Results:
- Plumbagin directly binds to and inhibits CRM1.
- Plumbagin causes tumor suppressor proteins to accumulate in the nucleus.
- Specific reaction of plumbagin with Cys(528) of CRM1 was confirmed.
- Cancer cells with mutant CRM1 (C528S) showed resistance to plumbagin's effects.
Conclusions:
- Plumbagin's anti-tumor effects are mediated by direct inhibition of CRM1 at Cys(528).
- Inhibition of nuclear transport by plumbagin may underlie its therapeutic benefits in cancer and inflammatory diseases.
- These findings support the development of novel CRM1 inhibitors for cancer therapy.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation
01:06Induced Pluripotent Stem Cells
Somatic...
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity